SWOG clinical trial number
              SWOG-8940
          A Phase I Study of the Combination of Recombinant Human Interleukin 1-Beta, Etoposide, and Carboplatin in Patients with Metastatic Cancer
Closed
      
  Phase
              Accrual
  
                          
      100%
      
  
    Published
      
  Abbreviated Title
              A Phase I Study of the Combination of Recombinant Human Interleukin 1-Beta, Etoposide, and Carboplatin in Patients with Metastatic Cancer
          Activated
              03/01/1990
          Closed
              11/01/1992
          Publication Information Expand/Collapse
1997
Phase 1 trial of recombinant human interleukin 1B (rhIL-1B), and etoposide in patients with solid cancers: Southwest Oncology Group study 8940
